Author

Kathryn Lucas

OpenAlex ID: A5126900807

Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial

2026 · Julio Rosenstock, Daisuke Yabe, et al. · The Lancet · 38

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity

2026 · Klara R. Klein, Jeremy Pettus, et al. · Diabetes Care

Works count: 2

Citation count: 38

H-index: 1

I10-index: 1